Collectively, this preclinical evidence, based on the examination of a primary lung carcinoma model and clinical samples, suggested that ACSL6 can be a potential clinical adjuvant candidate target which can provide novel strategy with better radiotherapeutic effects. Here, ACSL6 is linked to lung carcinoma.